INSP Stock Recent News

There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.

Investors need to pay close attention to INSP stock based on the movements in the options market lately.

Inspire Medical's growth remains strong, with 2025 seen as a transition year due to the Inspire V launch, causing near-term margin volatility. Valuations look more attractive: shares trade at just 4x sales, a significant discount from previous highs, while the business is profitable and growing. Concerns about GLP-1 drugs impacting demand are likely overblown, as these patients were not ideal candidates for Inspire's therapy anyway.

MINNEAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025. Inspire is scheduled to present at 11:20 a.m.

MINNEAPOLIS, May 30, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will participate in the Wells Fargo 2025 MedTech Innovation Spotlight on Friday, June 13, 2025.

OCALA, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- The Dr. Jose Jacob Scholarship for Future Doctors is now officially open for applications, offering a one-time award of $1,000 to undergraduate students across the United States who are committed to pursuing a career in medicine.

Inspire (INSP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The consensus price target hints at a 39% upside potential for Inspire (INSP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Inspire Medical's first-quarter 2025 performance reflects increased market penetration in existing centers and expansion into new territories and centers, along with strong domestic results.

Inspire Medical Systems, Inc. (NYSE:INSP ) Q1 2025 Results Conference Call May 5, 2025 5:00 PM ET Company Participants Ezgi Yagci - Vice President of Investor Relations Tim Herbert - President & Chief Executive Officer Rick Buchholz - Chief Financial Officer Conference Call Participants Kallum Titchmarsh - Morgan Stanley David Rescott - Baird Michael Sarcone - Jefferies Shagun Singh - RBC Chris Pasquale - Nephron Research Larry Biegelsen - Wells Fargo Anthony Petrone - Mizuho Financial Group Jon Block - Stifel Brett Fishbin - KeyBanc Capital Markets Michael Polark - Wolfe Research Travis Steed - Bank of America Securities Danielle Antalffy - UBS Robbie Marcus - JPM Adam Maeder - Piper Sandler Richard Newitter - Truist Operator Good afternoon. My name is Dilem and I'll be your conference operator today.